Assessment of the Regulatory Dialogue Between Pharmaceutical Companies and the European Medicines Agency on the Choice of Noninferiority Margins-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Assessment of the Regulatory Dialogue Between Pharmaceutical Companies and the European Medicines Agency on the Choice of Noninferiority Margins

Published:2020-08 Issue:8 Volume:42 Page:1588-1594
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Althunian Turki A.,de Boer Anthonius,Mantel-Teeuwisse Aukje K.,Groenwold Rolf H.H.,Gispen-de Wied Christine C.,Leufkens Hubert G.M.,Klungel Olaf H.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference20 articles.

1. Defining the non-inferiority margin and analyzing non-inferiority: an overview;Althunian;Br J Clin Pharmacol,2017

2. How to use a noninferiority trial: users' guides to the medical literature;Mulla;JAMA,2012

3. Noninferiority trials: is a new treatment almost as effective as another?;Kaji;JAMA,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daily Glucose Profiles after Switching from Injectable to Oral Semaglutide in Patients with Type 2 Diabetes Mellitus;Internal Medicine;2024-01-01

2. The Clinical Interpretation of Noninferiority Trials;Inflammatory Bowel Diseases;2023-12-30

3. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial;Nature Medicine;2022-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP